FDA approves new treatment for postpartum depression
The FDA has approved the first drug specifically designed to treat postpartum depression. In the U.S., about one in nine mothers experience depression after having a baby. As Dr. Tara Narula reports, the new drug is providing hope.
Conclusions No statistically significant association between bothersome urinary symptoms and the odds of screening positive for increased risk of postpartum depression was found. Future work in this area is needed.
In Canada, about 23 per cent of mothers who recently gave birth reported feelings consistent with either postpartum depression or an anxiety disorder.
This study aimed to systematically review and assess the evidence regarding the association between dieta...
AbstractPurposeOBGYNs help patients plan families, conceive, and deliver children, however the personal reproductive history and goals, infertility experiences, and birth outcomes of OBGYNs are not well studied. We aim to characterize female OBGYN reproductive experiences with a particular focus on infertility, reproductive life planning (methods of pregnancy prevention, reasons why pregnancy is/was delayed), birth outcomes (mode of delivery, delivery timing), and the postpartum period (breastfeeding, mat ernity leave, postpartum depression).DescriptionAn anonymous email survey was distributed to female members of Ge...
Publication date: July 2019Source: The Lancet Psychiatry, Volume 6, Issue 7Author(s): The Lancet Psychiatry
Al-Haddad BJS, Jacobsson B, Chabra S, Modzelewska D, Olson EM, Bernier R, et al. Long-term Risk of Neuropsychiatric Disease After Exposure to Infection In Utero. JAMA Psychiatry 2019, in press.
This study aimed to investigate the relationship between breastfeeding and postpartum depression (PPD) and it included 333 Taiwanese pregnant women. Women who had a higher score of Edinburgh Postnatal Depression Scale (EPDS) were significant older (age ≥ 35, p
Conclusions for PracticeThis research highlights the lack of effectiveness of existing treatment for maternal psychological distress both to benefit child development and to provide long-term symptom remediation for women. Future research could aim to identify more effective treatments for both women and children.
ConclusionsResults support proceeding to a definitive RCT to evaluate tDCS for antenatal depression. The preliminary efficacy estimates immediately post-treatment and in the postpartum, are encouraging with respect to the potential use of tDCS to improve treatment rates in this population. The trial was registered at: clinical trials.gov (NCT02116127).
An expert in perinatal psychopharmacology describes how this novel drug works in the management of postpartum depression, and the challenges posed by its safety requirements.Medscape Ob/Gyn